Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 72

recruiting
3 987
countries
28
conditions
2 109

1 026 trials match your criteria

Study on the Safety and Tolerability of BMS-986435 in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986435

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Active Psoriatic Arthritis in Patients with Inadequate Response to One Prior Anti-TNF Agent

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab

Study on Tafasitamab and Lenalidomide with Standard Therapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab

Psoriasis

Not recruiting

Study on the Safety, Effectiveness, and Blood Movement of Bimekizumab in Adolescents with Moderate to Severe Plaque Psoriasis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Bimekizumab

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Vitiligo

Not recruiting

Study on the Safety and Effectiveness of Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dexamethasone

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten

Myasthenia gravis+1

Not recruiting

Study on Ublituximab and Drug Combination for Patients with Myasthenia Gravis or Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine

Study Comparing RBS-001 and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept

Asthma

Not recruiting

Study on the Effects of Mepolizumab for Achieving Clinical Remission in Patients with Severe Asthma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Mepolizumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.